June 2025 marked a month of significant progress in cancer care, as the FDA approved several new therapies and treatment combinations across a range of cancer types. As reported by CureToday.com, these decisions reflect ongoing advances in personalized medicine and commitment to expanding options for patients with challenging diagnoses.
Datroway Offers Hope for Heavily Pretreated Lung Cancer
Datroway (datopotamab deruxtecan-dlnk) received accelerated approval for adults with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations. This new therapy is specifically for patients whose cancer has progressed after both EGFR-targeted medicine and platinum chemotherapy. In clinical trials, Datroway demonstrated a 45% overall response rate among heavily pretreated patients, with responses lasting a median of 6.5 months—highlighting a promising new option for a population with few alternatives.
Illuccix Expands Personalized Prostate Cancer Care
Illuccix, a kit that helps prepare the imaging agent gallium Ga‑68 gozetotide, gained expanded approval to select patients with metastatic castration-resistant prostate cancer for PSMA-targeted radioligand therapies. This will enable clinicians to better identify who may benefit from these advanced treatments before starting chemotherapy, supporting a more personalized approach and potentially increasing the number of eligible patients by over 20,000 annually.
Combination Therapy for Relapsed Follicular Lymphoma
Monjuvi (tafasitamab-cxix), when combined with Revlimid and Rituxan, is now approved for follicular lymphoma that has returned or not responded to prior treatments. In clinical trials, this combination prolonged the time patients lived without disease progression to a median of 22.4 months, compared to 13.9 months for those not receiving Monjuvi, offering renewed hope in this relapsed setting.
Brukinsa Tablet Simplifies Blood Cancer Treatment
A new tablet form of Brukinsa (zanubrutinib) is now available for all its approved uses, including several types of blood cancers. The tablet formulation aims to make treatment simpler and more convenient for patients facing complex regimens.
Keytruda Approved for Head and Neck Cancer Before and After Surgery
Keytruda (pembrolizumab) received approval for perioperative use in adults with resectable, locally advanced head and neck squamous cell carcinoma that tests positive for PD-L1. This is the first approval covering both before and after surgery treatment for this cancer type, and nearly doubled event-free survival in clinical trials compared to standard care.
Ibtrozi for ROS1+ Lung Cancer
Ibtrozi (taletrectinib) was approved for advanced NSCLC with ROS1 gene alterations. In untreated patients, response rates were as high as 90%, and the majority maintained benefit for at least a year.
Nubeqa in Metastatic Castration-Sensitive Prostate Cancer
Nubeqa (darolutamide) is now approved for use in metastatic castration-sensitive prostate cancer, extending the time patients live without disease worsening and providing new options for individualized care.
Conclusion
The diverse FDA approvals from June 2025 underscore an encouraging trend toward more targeted, effective, and convenient cancer therapies. Patients and clinicians now have access to a broader arsenal of treatments tailored to specific genetic profiles, cancer stages, and individual preferences—bringing new hope and opportunity for improved outcomes across the oncology spectrum.
